Eli Lilly to expand 340B reporting requirements

(By: Ella Jeffries for Becker’s Hospital Review)

Eli Lilly and Co. will require all 340B covered entities to submit claims-level data for in-house pharmacy dispensing beginning Feb. 1, 2026.

The new requirement expands Lilly’s existing policy, which has applied to contract pharmacies since December 2021, according to a Jan. 15 company news release. All covered entity types must report claims-level data for Lilly’s full product portfolio — under labeler codes 00002, 00077 and 66733 — to the 340B ESP platform within 45 days of product dispense. For certain infused and administered products, data must be submitted within 60 days of administration. Those products are Alimta, Amyvid, Cyramza, Erbitux, Kisunla, Omvoh, Portrazza and Tauvid. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.